Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (Xijing Hospital)
- Development stage
- Unknown
- Lead developer
- Xijing Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are an investigational cell therapy developed by Xijing Hospital for the treatment of moderate to severe rheumatoid arthritis (RA), particularly in patients with associated anemia or interstitial lung disease. These multipotent cells exhibit significant immunomodulatory properties, including the ability to inhibit the proliferation and activation of pro-inflammatory T cells and B cells, while promoting the expansion of regulatory T cells (Tregs). The therapeutic effect is mediated through the secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), as well as enzymes like indoleamine 2,3-dioxygenase (IDO). By modulating the systemic immune response and reducing the production of pro-inflammatory mediators, UC-MSCs aim to restore immune homeostasis, reduce joint inflammation, and improve clinical outcomes in RA patients who may not respond adequately to conventional disease-modifying antirheumatic drugs (DMARDs).
- Other names
- human umbilical cord blood mesenchymal stem cellsUC-MSCsumbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (Xijing Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Xijing Hospital).